 |
|
| Blog results | Results 1 - 10 of about 7,214 for capecitabine treatment. (0.28 seconds) |
| Sorted by relevance Sort by date |
| 24 Nov 2009 The National Institute for Health and Clinical Excellence has issued an appraisal consultation document on the use of bevacizumab in combination with oxaliplatin and either 5-fluorouracil or capecitabine for the treatment of metastatic ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 24 Nov 2009 Addition of capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival. However, increased adverse events mean treatment with capecitabine is frequently dis. ecancer news - http://www.ecancermedicalscience.com/ |
| 24 Jul 2009 by Dr. Charles Balch Capecitabine (XELODA, Roche) is the first FDA-approved oral chemotherapy for the treatment of both metastatic breast and colorectal cancers. The drug is approved for use in colorectal cancer, both as adjuvant therapy after surgery for ... My Cancer Advisor - http://mycanceradvisor.com/ [ More results from My Cancer Advisor ] |
| 17 Nov 2009 by Syn-chemist The pre-planned three-year interim analysis of a randomised, prospective trial compared adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for the treatment of early breast cancer with the standard, ... Med-Chemist - http://synchemist.blogspot.com/ |
| 11 Nov 2009 FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 12 Nov 2009 by HSPDi The prospective trial (known as FinXX) compared adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for the treatment of early breast cancer with the standard, non-capecitabine regimen (docetaxel, ... pharma news - http://www.pharmajobs.co.uk/blog/ [ More results from pharma news ] |
| 12 Nov 2009 by Dr. NICK They also point out that adding capecitabine to the treatment regimen was associated with frequent discontinuation of planned chemotherapy, although most patients were able to tolerate all of the scheduled cycles. ... CANCER AND IMPORTANT MEDICAL NEWS - http://cancerology.blogspot.com/ |
| 23 Oct 2009 “These new data show that adding capecitabine to epirubicin and docetaxel [Taxotere] neoadjuvant regimens when treating women with early breast cancer, results in increased efficacy compared to epirubicin and docetaxel alone. ... Cancer Network - http://www.cancernetwork.com/ [ More results from Cancer Network ] |
| 20 hours ago by pillscribe Preliminary recommendations published estimated that Avastin plus XELOX (capecitabine, oxaliplatin) as a first-line CRC treatment produced an incremental cost effectiveness ratio of GBP36,400 per QALY compared to XELOX alone. ... DWS Pill Scribe - http://www.dancewithshadows.com/pillscribe/ [ More results from DWS Pill Scribe ] |
| 15 Nov 2009 Although capecitabine added to chemotherapy for breast cancer improves survival rates, side-effects will force some patients to discontinue the treatment, according to trials. A report by Professor Heikki Joensuu and colleagues at ... Pharmacy Europe - http://www.pharmacyeurope.net/rss.asp - References [ More results from Pharmacy Europe ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
